


LISTING OF THE CLAIMS

This Listing of Claims will replace all prior versions and listings of claims in the above-referenced patent application:

- 1.-6. (Cancelled)
7. (Previously Presented) An intravenous aqueous pharmaceutical formulation comprising:

a) an anti-ulcerative compound having the following formula:



or a pharmaceutically acceptable salt thereof;

b) glycine; and

c) a tonicity agent;

wherein the molecular ratio of glycine to anti-ulcerative compound is between 0.43:1 and 1:1; and

wherein the formulation is suitable for intravenous administration.

8. (Previously Presented) The intravenous aqueous pharmaceutical formulation of claim 7, wherein the tonicity agent is selected from the group consisting of sodium chloride and dextrose.


9. (Previously Presented) The intravenous aqueous pharmaceutical formulation of claim 8, wherein the tonicity agent is sodium chloride and the sodium chloride is present in the formulation at a concentration of about 0.9% by weight.

10. (Previously Presented) The intravenous aqueous pharmaceutical formulation of claim 8, wherein the tonicity agent is dextrose and the dextrose is present in the formulation at a concentration of about 5% by weight.

11.-23. (Cancelled)

24. (Presently amended) A lyophilized pharmaceutical formulation ~~in a sealable container the formulation~~ comprising:

a) a) an anti-ulcerative compound having the following formula:



or a pharmaceutically acceptable salt thereof;

b) glycine; and

c) NaOH; and

wherein the molecular ratio of glycine to anti-ulcerative compound is between 0.43:1 and 1:1.

~~wherein the container is sealed such that exchange of air between the inside of the sealable container and the external environment of the container is not possible.~~